2022 年世界卫生组织分类对 PitNETS 患者多学科管理的临床影响。

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM Minerva endocrinology Pub Date : 2024-07-04 DOI:10.23736/S2724-6507.24.04126-5
Miriam Veleno, Antonella Giampietro, Salvatore Raia, Sara Menotti, Tommaso Tartaglione, Simona Gaudino, Francesco Doglietto, Laura DE Marinis, Alfredo Pontecorvi, Sabrina Chiloiro, Antonio Bianchi
{"title":"2022 年世界卫生组织分类对 PitNETS 患者多学科管理的临床影响。","authors":"Miriam Veleno, Antonella Giampietro, Salvatore Raia, Sara Menotti, Tommaso Tartaglione, Simona Gaudino, Francesco Doglietto, Laura DE Marinis, Alfredo Pontecorvi, Sabrina Chiloiro, Antonio Bianchi","doi":"10.23736/S2724-6507.24.04126-5","DOIUrl":null,"url":null,"abstract":"<p><p>The review explores the 2022 update to the World Health Organization (WHO) classification of pituitary adenomas, now referred to as pituitary neuroendocrine tumors (PitNETs), and his possible impact on the clinical management of PitNET patients. The review highlights the differences and the evolution from the 2017 to 2022 version, with the current classification considering the lineage of the tumor cells, cell type, hormones produced, and other auxiliary characteristics for a comprehensive histological classification. The revision in terminology reflects a broader perspective on neuroendocrine neoplasia. The new approach based on transcription factors, hormone expression and other biomarkers has allowed a major revision of the nomenclature and a more accurate classification of pituitary adenomas. Furthermore, in some cases this approach is also assuming a prognostic value, useful in clinical practice. However, despite this elaborate classification and stratification, the review points out the lack of a robust grading or staging system and suggests the need for further research and validation of diagnostic methods. Despite these limitations, the revised classification presents a significant step towards understanding and managing PitNETs patients.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients.\",\"authors\":\"Miriam Veleno, Antonella Giampietro, Salvatore Raia, Sara Menotti, Tommaso Tartaglione, Simona Gaudino, Francesco Doglietto, Laura DE Marinis, Alfredo Pontecorvi, Sabrina Chiloiro, Antonio Bianchi\",\"doi\":\"10.23736/S2724-6507.24.04126-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The review explores the 2022 update to the World Health Organization (WHO) classification of pituitary adenomas, now referred to as pituitary neuroendocrine tumors (PitNETs), and his possible impact on the clinical management of PitNET patients. The review highlights the differences and the evolution from the 2017 to 2022 version, with the current classification considering the lineage of the tumor cells, cell type, hormones produced, and other auxiliary characteristics for a comprehensive histological classification. The revision in terminology reflects a broader perspective on neuroendocrine neoplasia. The new approach based on transcription factors, hormone expression and other biomarkers has allowed a major revision of the nomenclature and a more accurate classification of pituitary adenomas. Furthermore, in some cases this approach is also assuming a prognostic value, useful in clinical practice. However, despite this elaborate classification and stratification, the review points out the lack of a robust grading or staging system and suggests the need for further research and validation of diagnostic methods. Despite these limitations, the revised classification presents a significant step towards understanding and managing PitNETs patients.</p>\",\"PeriodicalId\":18690,\"journal\":{\"name\":\"Minerva endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S2724-6507.24.04126-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.24.04126-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

这篇综述探讨了世界卫生组织(WHO)2022年更新的垂体腺瘤(现称为垂体神经内分泌肿瘤(PitNETs))分类及其对PitNET患者临床管理可能产生的影响。综述强调了从2017年版到2022年版的差异和演变,目前的分类考虑了肿瘤细胞的系谱、细胞类型、产生的激素和其他辅助特征,以进行全面的组织学分类。术语的修订反映了神经内分泌肿瘤的更广阔视角。基于转录因子、激素表达和其他生物标志物的新方法对术语进行了重大修订,使垂体腺瘤的分类更加准确。此外,在某些情况下,这种方法还具有预后价值,在临床实践中非常有用。不过,尽管进行了详细的分类和分层,但综述指出,目前还缺乏一个健全的分级或分期系统,并建议需要进一步研究和验证诊断方法。尽管存在这些局限性,但修订后的分类在理解和管理 PitNETs 患者方面迈出了重要一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients.

The review explores the 2022 update to the World Health Organization (WHO) classification of pituitary adenomas, now referred to as pituitary neuroendocrine tumors (PitNETs), and his possible impact on the clinical management of PitNET patients. The review highlights the differences and the evolution from the 2017 to 2022 version, with the current classification considering the lineage of the tumor cells, cell type, hormones produced, and other auxiliary characteristics for a comprehensive histological classification. The revision in terminology reflects a broader perspective on neuroendocrine neoplasia. The new approach based on transcription factors, hormone expression and other biomarkers has allowed a major revision of the nomenclature and a more accurate classification of pituitary adenomas. Furthermore, in some cases this approach is also assuming a prognostic value, useful in clinical practice. However, despite this elaborate classification and stratification, the review points out the lack of a robust grading or staging system and suggests the need for further research and validation of diagnostic methods. Despite these limitations, the revised classification presents a significant step towards understanding and managing PitNETs patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
146
期刊最新文献
Assessing the impact of a dedicated referral and management algorithm in maternal hypothyroidism. Divulging the overlooked condition: diabetic ketoacidosis as an imminent risk with sodium-glucose co-transporter-2 inhibitors treatment in type 2 diabetes mellitus. Obesity prevention across the lifespan: assessing the efficacy of intervention studies and discussing future challenges. Adherence to Mediterranean diet and prevalence of differentiated thyroid cancer: a single-center Unit of Thyroid Surgery experience in a Southern-Italy cohort. Follicle-stimulating hormone receptor gene polymorphisms influence Body Mass Index, metabolism, and bone mineral density in postmenopausal women.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1